John Tomtishen | Global Head of Field Application Scientists and Strategic Alliances
Catalent

John Tomtishen is a cell therapy industry veteran and recognized CMC leader within biopharmaceutical manufacturing having served in diverse business and technical roles throughout his career. John is currently the Global Head Cell Therapy, Field Application Scientists and Strategic Alliances at Catalent where he is working to build out partnerships to drive Catalent’s Cell Therapy Business and support drug sponsors across the cell therapy development lifecycle. Prior to joining Catalent, John oversaw the global buildout of the IDMO business at Cellares and played a critical role in driving strategic collaborations and partnerships with cell therapy developers from pre-clinical development to post-commercial licensure. Earlier in his career, John played pivotal roles in the filing and approval of the first CAR-T cell therapy Kymriah™ while at Novartis, and the clinical development and commercial filing of Carvykti™ at Legend Biotech.